CYBN.NE
Price:
$14
Market Cap:
$279.89M
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.[Read more]
Industry
Biotechnology
IPO Date
2020-11-10
Stock Exchange
NEO
Ticker
CYBN.NE
According to Cybin Inc.’s latest financial reports and current stock price. The company's current ROE is -40.40%. This represents a change of 203.99% compared to the average of -13.29% of the last 4 quarters.
The mean historical ROE of Cybin Inc. over the last ten years is -329.01%. The current -40.40% ROE has changed -87.72% with respect to the historical average. Over the past ten years (40 quarters), CYBN.NE's ROE was at its highest in in the December 2019 quarter at 0%. The ROE was at its lowest in in the June 2020 quarter at -65.71%.
Average
-329.01%
Median
-60.99%
Minimum
-2225.14%
Maximum
0%
Discovering the peaks and valleys of Cybin Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.56%
Maximum Annual ROE = 0%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -2225.14%
Year | ROE | Change |
---|---|---|
2024 | -26.75% | -72.83% |
2023 | -98.46% | 25.37% |
2022 | -78.53% | -96.47% |
2021 | -2225.14% | 1.56% |
2020 | -134.25% | 427.17% |
2019 | -25.47% | -Infinity% |
2018 | 0% | -100.00% |
The current ROE of Cybin Inc. (CYBN.NE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-67.91%
5-year avg
-512.63%
10-year avg
-329.01%
Cybin Inc.’s ROE is greater than Red Light Holland Corp. (-32.73%), greater than Mind Medicine (MindMed) Inc. (-105.28%), greater than Revive Therapeutics Ltd. (-61.00%), greater than HAVN Life Sciences Inc. (-302.07%), greater than Numinus Wellness Inc. (-261.92%),
Company | ROE | Market cap |
---|---|---|
-32.73% | $13.97M | |
-105.28% | $1.05B | |
-61.00% | $1.05M | |
-302.07% | $442.16K | |
-261.92% | $8.06M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cybin Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cybin Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Cybin Inc.'s ROE?
How is the ROE calculated for Cybin Inc. (CYBN.NE)?
What is the highest ROE for Cybin Inc. (CYBN.NE)?
What is the 3-year average ROE for Cybin Inc. (CYBN.NE)?
What is the 5-year average ROE for Cybin Inc. (CYBN.NE)?
How does the current ROE for Cybin Inc. (CYBN.NE) compare to its historical average?